xDRIVE in Metastatic Colorectal Cancer
Key facts
- Who runs it
- First Ascent Biomedical Inc.
- Trial code
- Status
- Withdrawn
- Started
- 15 Sept 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Observational
- Treatments tested
- Functional precision medicine
- Record updated
- 2 September 2026
- Why it stopped
- Unable to finalize study agreements
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participants (men and women) enrolled in internal review board (IRB) 622-00 and meet the following criteria
- Participants ≥18 years of age with a diagnosis of mCRC who are willing to consent to the study
- Participants with Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2
- Participants with measurable disease
- Participants who need to start SOC cancer-directed systemic therapy
- Participants able to provide treatment and outcome information from previous lines of therapy
- Participants who will need a tumor biopsy, excision, or resection as part of their routine clinical care
- Participants willing to have a blood draw performed for matched normal material
- Participants who plan to have their first radiographic assessment of their cancer at Mayo Clinic
Who cannot take part
- Participants with other concurrent cancers besides mCRC which also require ongoing cancer-directed therapy
- Participants who do not have malignant tissue available or safely accessible or do not have sufficient amount of tissue from anticipated biopsy, excision or resection for testing
- Participants who do not have measurable disease
- Participants with insufficient health indicators to undergo therapeutic intervention for mCRC based on treating oncologist's clinical assessment
- Participants who cannot provide an informed consent
About the trial
What the trial wants to find out
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC). The primary objective is to assess xDRIVE's accuracy in forecasting clinical benefit from standard-of-care (SOC) therapies, with a target of ≥80% accuracy in 25 participants. Achieving this threshold would provide sufficient statistical power to reject the null hypothesis of ≤50% accuracy.
Read full original descriptionShow less
The secondary goal is to determine the feasibility of utilizing xDRIVE for timely treatment recommendations. Success will be defined by the ability to provide recommendations within four weeks for at least 64% of patients, ensuring clinical applicability.
Additionally, the study includes an exploratory objective to examine oncologists' perspectives on integrating xDRIVE into clinical decision-making. This will be achieved through a post-hoc survey assessing physician experiences with the precision oncology platform.
The group in the trial
- Metastatic colorectal cancer patients
Participants with mCRC who need clinical tumor biopsy or resection and need to start systemic therapy for measurable disease.
Treatment: Functional precision medicine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Feasibility Study to Evaluate a Precision Oncology Platform (xDRIVE) in Participants With Advanced Colorectal Cancer
- Record updated
- 2 September 2026